Extended Data Fig. 6: Internal validation of proposed 3-stage screening strategy in the test set only.
From: Proteomic signatures for identification of impaired glucose tolerance
In the first stage, individuals in the Fenland test set were divided into low and high risk according to the Cambridge T2D risk score. The high risk group would undergo a second stage involving measurement of HbA1c and of the 3 iIGT proteins. Individuals with HbA1c levels within the T2D or prediabetic range would be referred for intervention and lifestyle modifications. Individuals with HbA1c below the prediabetic range, would further stratified using the final clinical + 3 iIGT protein model to identify a high risk group, which on a third stage would be taken forward for OGTT testing to identify iIGT cases that would have been otherwise by current screening guidelines. The NNS in the strata of individuals at high predicted risk based on the patient-derived information model, but HbA1c levels below cut-offs for prediabetes (N = 1043) was 14, while by additionally applying the clinical + 3-protein iIGT model the NNS was of only 5 (N = 88 at high-risk). Figure was designed with biorender.com.
